These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35810827)

  • 1. Urate Transporter ABCG2 Function and Asymptomatic Hyperuricemia: A Retrospective Cohort Study of CKD Progression.
    Ohashi Y; Kuriyama S; Nakano T; Sekine M; Toyoda Y; Nakayama A; Takada T; Kawamura Y; Nakamura T; Matsuo H; Yokoo T; Ichida K
    Am J Kidney Dis; 2023 Feb; 81(2):134-144.e1. PubMed ID: 35810827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of normal level of serum urate may contribute to decrease in estimated glomerular filtration rate decline in healthy Japanese men.
    Kuma A; Mafune K; Uchino B; Ochiai Y; Enta K; Kato A
    Ren Fail; 2021 Dec; 43(1):1408-1415. PubMed ID: 34633265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
    Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients.
    Ohashi Y; Toyoda M; Saito N; Koizumi M; Kanai G; Komaba H; Kimura M; Wada T; Takahashi H; Takahashi Y; Ishida N; Kakuta T; Fukagawa M; Ichida K
    Sci Rep; 2023 Jan; 13(1):93. PubMed ID: 36639673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCG2 dysfunction increases the risk of renal overload hyperuricemia.
    Matsuo H; Takada T; Nakayama A; Shimizu T; Sakiyama M; Shimizu S; Chiba T; Nakashima H; Nakamura T; Takada Y; Sakurai Y; Hosoya T; Shinomiya N; Ichida K
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):266-74. PubMed ID: 24940678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors.
    Nakayama A; Matsuo H; Nakaoka H; Nakamura T; Nakashima H; Takada Y; Oikawa Y; Takada T; Sakiyama M; Shimizu S; Kawamura Y; Chiba T; Abe J; Wakai K; Kawai S; Okada R; Tamura T; Shichijo Y; Akashi A; Suzuki H; Hosoya T; Sakurai Y; Ichida K; Shinomiya N
    Sci Rep; 2014 Jun; 4():5227. PubMed ID: 24909660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bidirectional Relationship between Chronic Kidney Disease and Hyperuricemia: Evidence from a Population-Based Prospective Cohort Study.
    Ma Z; Wang X; Zhang J; Yang C; Du H; Dou F; Li J; Zhao Y; Quan P; Hu X
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
    Nakayama A; Matsuo H; Takada T; Ichida K; Nakamura T; Ikebuchi Y; Ito K; Hosoya T; Kanai Y; Suzuki H; Shinomiya N
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1091-7. PubMed ID: 22132962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.
    Eckenstaler R; Benndorf RA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the increase in serum uric acid and the rapid decline in kidney function in adults with normal kidney function: a retrospective study in Urumqi, China.
    Li N; Yang X; Wu J; Wang Y; Wang Z; Mu H
    BMC Nephrol; 2023 Apr; 24(1):103. PubMed ID: 37085795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactive association of baseline and changes in serum uric acid on renal dysfunction among community-dwelling persons.
    Kawamoto R; Ninomiya D; Akase T; Kikuchi A; Kumagi T
    J Clin Lab Anal; 2020 May; 34(5):e23166. PubMed ID: 31880007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function.
    Toyama T; Furuichi K; Shimizu M; Hara A; Iwata Y; Sakai N; Perkovic V; Kobayashi M; Mano T; Kaneko S; Wada T
    PLoS One; 2015; 10(9):e0137449. PubMed ID: 26356235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCG2 as a therapeutic target candidate for gout.
    Fujita K; Ichida K
    Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
    Jeon HJ; Oh J; Shin DH
    PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients.
    Nakashima A; Ichida K; Ohkido I; Yokoyama K; Matsuo H; Ohashi Y; Takada T; Nakayama A; Suzuki H; Shinomiya N; Urashima M; Yokoo T
    Hum Cell; 2020 Jul; 33(3):559-568. PubMed ID: 32180207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
    Woodward OM; Köttgen A; Coresh J; Boerwinkle E; Guggino WB; Köttgen M
    Proc Natl Acad Sci U S A; 2009 Jun; 106(25):10338-42. PubMed ID: 19506252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.
    Matsuo H; Nakayama A; Sakiyama M; Chiba T; Shimizu S; Kawamura Y; Nakashima H; Nakamura T; Takada Y; Oikawa Y; Takada T; Nakaoka H; Abe J; Inoue H; Wakai K; Kawai S; Guang Y; Nakagawa H; Ito T; Niwa K; Yamamoto K; Sakurai Y; Suzuki H; Hosoya T; Ichida K; Shimizu T; Shinomiya N
    Sci Rep; 2014 Jan; 4():3755. PubMed ID: 24441388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Characterization of Clinically-Relevant Rare Variants in
    Toyoda Y; Mančíková A; Krylov V; Morimoto K; Pavelcová K; Bohatá J; Pavelka K; Pavlíková M; Suzuki H; Matsuo H; Takada T; Stiburkova B
    Cells; 2019 Apr; 8(4):. PubMed ID: 31003562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.